Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir versus efavirenz 400 mg in pregnant and breastfeeding women with HIV
PACTR201909810587438Phase 4Recruiting
- Sponsor
- Hawassa University
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial in human immunodeficiency virus infection (HIV) comparing Dolutegravir arm with Efavirenz 400 mg arm (2 arms). Primary endpoints: Virological suppression at delivery and Mother-to-child transmission of HIV. Started Jun 2019; status: recruiting.
02
Drugs
dolutegravirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201909810587438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201909810587438.